Verzenio

Introduction Verzenio is the brand name of abemaciclib, an oral targeted anticancer drug used in selected patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Pharmacologically, Verzenio belongs to the cyclin-dependent kinase 4 and 6 inhibitor class, commonly called CDK4/6 inhibitors. CDK4 and CDK6 are key enzymes that regulate progression of cells … Read more